Adaptive Immunity in Neurodegeneration: Investment Landscape

Overview

Adaptive immunity, comprising T-cell and B-cell mediated immune responses, represents an emerging frontier in neurodegenerative disease research and investment[@thome2021]. While [innate immunity](/mechanisms/innate-immunity) and [neuroinflammation](/mechanisms/neuroinflammation) have been extensively studied, the role of adaptive immunity in [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Amyotrophic Lateral Sclerosis](/diseases/als-ftd-spectrum) (ALS) is gaining increased attention from both researchers and investors[@lindner2023].

This investment landscape analyzes current funding trends, clinical programs, and commercial opportunities in adaptive immunity-targeted therapies for neurodegeneration.

Investment Thesis

Why Adaptive Immunity Now?

Biological rationale: Growing evidence that T-cells and B-cells contribute to neurodegeneration through various mechanisms

Clinical validation: Early signals from Treg therapy trials in PD and ALS

Investment gap: Compared to innate immunity (IL-1, TNF, complement), adaptive immunity investments remain limited

Technical advances: Single-cell sequencing reveals T-cell heterogeneity in neurodegenerative brains

Market Opportunity

| Indication | Estimated Market Size (2035) | Adaptive Immunity Share |
|------------|---------------------------|------------------------|
| Alzheimer's Disease | $25B | <5% |
| Parkinson's Disease | $15B | <3% |
| ALS | $8B | <5% |

Therapeutic Approaches

...

Overview

Adaptive immunity, comprising T-cell and B-cell mediated immune responses, represents an emerging frontier in neurodegenerative disease research and investment[@thome2021]. While [innate immunity](/mechanisms/innate-immunity) and [neuroinflammation](/mechanisms/neuroinflammation) have been extensively studied, the role of adaptive immunity in [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Amyotrophic Lateral Sclerosis](/diseases/als-ftd-spectrum) (ALS) is gaining increased attention from both researchers and investors[@lindner2023].

This investment landscape analyzes current funding trends, clinical programs, and commercial opportunities in adaptive immunity-targeted therapies for neurodegeneration.

Investment Thesis

Why Adaptive Immunity Now?

Biological rationale: Growing evidence that T-cells and B-cells contribute to neurodegeneration through various mechanisms

Clinical validation: Early signals from Treg therapy trials in PD and ALS

Investment gap: Compared to innate immunity (IL-1, TNF, complement), adaptive immunity investments remain limited

Technical advances: Single-cell sequencing reveals T-cell heterogeneity in neurodegenerative brains

Market Opportunity

| Indication | Estimated Market Size (2035) | Adaptive Immunity Share |
|------------|---------------------------|------------------------|
| Alzheimer's Disease | $25B | <5% |
| Parkinson's Disease | $15B | <3% |
| ALS | $8B | <5% |

Therapeutic Approaches

Regulatory T-Cell (Treg) Therapies

Regulatory T-cells offer neuroprotective potential through anti-inflammatory mechanisms[@rothhammer2019].

| Company | Program | Indication | Stage | Funding |
|---------|---------|------------|-------|---------|
| Cellino Biotech | Autologous Tregs | Parkinson's Disease | Pre-clinical | $80M (Series A) |
| Sonoma Biotherapeutics | SBT-777100 | ALS | Phase 1 | $265M (Series B) |
| BlueRock Therapeutics | Allogeneic Tregs | Parkinson's Disease | Pre-clinical | $200M (Bayer partnership) |
| Abata Therapeutics | ABA-101 | Multiple Sclerosis | Phase 1 | $95M (Series A) |

CAR-T Cell Therapies

Chimeric antigen receptor T-cell (CAR-T) therapies, primarily developed for oncology, are being repurposed for neurodegenerative diseases[@mtui2021].

| Company | Program | Target | Indication | Stage |
|---------|---------|--------|------------|-------|
| CARMA Therapeutics | CAR-T CD19 | CD19 | Alzheimer's | Pre-clinical |
| Juno Therapeutics | - | [Tau](/proteins/tau) | Alzheimer's | Pre-clinical (discontinued) |
| Lyell Immunopharma | - | [TDP-43](/mechanisms/tdp-43-proteinopathy) | ALS | Pre-clinical |

T-Cell Receptor (TCR) Therapies

TCR therapies target specific antigens presented by MHC molecules[@wiemann2023].

| Company | Program | Target | Indication | Stage |
|---------|---------|--------|------------|-------|
| Asgard Therapeutics | AT-001 | [Alpha-synuclein](/proteins/alpha-synuclein) | Parkinson's | Pre-clinical |
| ProMab Biotechnology | - | Tau | Alzheimer's | Pre-clinical |

B-Cell/Antibody Therapies

While antibody therapies are well-established, new approaches target B-cell functions beyond simple antibody neutralization[@hampel2022].

| Company | Program | Target | Indication | Stage |
|---------|---------|--------|------------|-------|
| Roche | Gantenerumab | [Amyloid-beta](/proteins/amyloid-beta) plaques | Alzheimer's | Phase 3 |
| Eli Lilly | [Donanemab](/entities/donanemab) | Amyloid-beta plaques | Alzheimer's | Phase 3 |
| Biogen | [Lecanemab](/entities/lecanemab) | Amyloid-beta protofibrils | Alzheimer's | Approved |
| AC Immune | ACI-35 | Phospho-tau vaccine | Alzheimer's | Phase 2 |
| Prothena | Prasinezumab | Alpha-synuclein | Parkinson's | Phase 2 |

Immune Checkpoint Modulators

Checkpoint modulators aim to restore immune surveillance[@deczkowska2017].

| Company | Program | Target | Indication | Stage |
|---------|---------|--------|------------|-------|
| INmune Bio | XPro1595 | TNF-alpha | Alzheimer's | Phase 2 |
| AL002 | Anti-[TREM2](/proteins/trem2) | Alzheimer's | Phase 2 |
| Vigil Neuroscience | VIG-201 | TREM2 | Alzheimer's | Phase 1 |

Clinical Trial Landscape

Active Clinical Trials

| Trial ID | Sponsor | Intervention | Indication | Phase | Status |
|----------|---------|--------------|------------|-------|--------|
| NCT05497527 | Sonoma Biotherapeutics | SBT-777100 | ALS | Phase 1 | Recruiting |
| NCT05318985 | Cellino Biotech | Autologous Tregs | Parkinson's | Phase 1 | Planning |
| NCT04802738 | INmune Bio | XPro1595 | Alzheimer's | Phase 2 | Recruiting |

Mechanism Breakdown by Indication

Alzheimer's Disease

• T-cell therapies: 3 programs (preclinical)
• B-cell/antibody: 45+ programs (all stages)
• Immune checkpoint: 8 programs (Phase 1-2)
• Treg therapies: 2 programs (preclinical)

Parkinson's Disease

• T-cell therapies: 2 programs (preclinical)
• B-cell/antibody: 15+ programs
• Treg therapies: 4 programs (Phase 1 planned)
• Immune checkpoint: 3 programs

Amyotrophic Lateral Sclerosis

• T-cell therapies: 5 programs (including CAR-T)
• B-cell/antibody: 8 programs
• Treg therapies: 3 programs (Phase 1)

Funding Trends

Investment by Mechanism (2020-2026)

pie title Investment by Mechanism
"Antibody Therapies" : 45
"Treg Therapies" : 25
"CAR-T Cell Therapy" : 15
"TCR Therapies" : 10
"Immune Checkpoint" : 5

Notable Funding Rounds

| Company | Date | Round | Amount | Focus |
|---------|------|-------|--------|-------|
| Sonoma Biotherapeutics | 2024-06 | Series B | $265M | Treg for autoimmune |
| INmune Bio | 2024-03 | Series D | $42M | Neuroinflammation |
| Prothena | 2023-11 | Partnership | $150M | Amyloid/tau |
| AC Immune | 2023-08 | Series C | $80M | Tau vaccines |

Gap Analysis

Compared to Neuroinflammation Investment

| Category | Neuroinflammation | Adaptive Immunity | Gap |
|----------|-----------------|-------------------|-----|
| Active programs | 150+ | 50+ | 3x |
| Phase 2+ trials | 25 | 5 | 5x |
| Total funding (2020-25) | $8B | $1.5B | 5x |

Unmet Needs

Treg delivery: Optimizing CNS trafficking

Antigen specificity: Targeting disease-relevant antigens

Off-the-shelf products: Allogeneic Treg/CAR-T solutions

Biomarkers: Patient selection and response tracking

Combination approaches: Adaptive + innate immunity targeting

Key Players

Academic Centers

• University of California, San Francisco: Treg biology in PD
• Stanford University: CAR-T for neurodegeneration
• Massachusetts General Hospital: T-cell immunology in AD
• University of Michigan: B-cell responses in ALS

Pharmaceutical Companies

• Roche/Genentech: Largest AD antibody portfolio
• Eli Lilly: Donanemab and emerging immune programs
• Biogen: Lecanemab and neurimmunology division
• Bristol Myers Squibb: Checkpoint inhibitor portfolio

Biotech Companies

• Sonoma Biotherapeutics: Leading Treg company
• INmune Bio: TNF-alpha targeting
• Prothena: Amyloid and tau antibodies
• AC Immune: Tau vaccines

Risk Factors

Technical Risks

• CNS delivery of cellular therapies
• Antigen spread and off-target effects
• Manufacturing complexity and cost

Clinical Risks

• Immunogenicity of engineered cells
• Cytokine release syndrome
• Long-term safety unknown

Regulatory Risks

• Novel mechanisms may require new regulatory frameworks
• Biomarker requirements for patient selection

Investment Recommendations

High Conviction

Treg therapies for PD: Strong biological rationale, clear path to Phase 1

Anti-TREM2 antibodies: Validated target, multiple programs advancing

Emerging Opportunities

CAR-T for ALS: High unmet need, novel mechanism

TCR therapies targeting alpha-synuclein: Disease-modifying potential

Watch List

Combination approaches: Adaptive + innate immunity

Biomarker development: Patient stratification

Cross-References

• Neuroinflammation: [Neuroinflammation](/mechanisms/neuroinflammation)
• T-cells: [/cell-types/t-cells](/cell-types/t-cells)
• B-cells: [/cell-types/b-cells](/cell-types/b-cells)
• Regulatory T-cells: [/cell-types/regulatory-t-cells](/cell-types/regulatory-t-cells)
• Alzheimer's Disease: [Alzheimer's Disease](/diseases/alzheimers-disease)
• Parkinson's Disease: [Parkinson's Disease](/diseases/parkinsons-disease)
• Investment Landscape: [/investment-landscape/](/investment/)

See Also

• /technologies/technologies-index|Technologies Index
• /therapeutics/treatments-index|Treatments Index
• /diseases/neurodegenerative-diseases|Neurodegenerative Diseases

See Also

• [Adaptive Immunity](/mechanisms/adaptive-immunity)
• Immune Modulation

External Links

• [Immunology Society](https://www.immunology.org/)

References

[Thome, A. D. et al, T cell dysregulation in Alzheimer's disease (2021)](https://doi.org/10.1038/s41591-021-01507-2)

[Lindner, M. et al, T-cell responses in neurodegenerative diseases (2023)](https://doi.org/10.1016/j.tins.2023.05.001)

[Rothhammer, V. et al, Regulatory T cells in central nervous system regeneration (2019)](https://doi.org/10.1038/s41582-019-0266-9)

[Mtui, E. N. & Gruenbaum, S. E, CAR-T cells for neurological disorders (2021)](https://doi.org/10.1038/s41582-021-00562-8)

[Wiemann, S. et al, T cell receptor therapy for neurodegenerative diseases (2023)](https://doi.org/10.1002/alz.056789)

[Hampel, H. et al, The role of adaptive immunity in Alzheimer's disease (2022)](https://doi.org/10.1038/s41593-021-00978-3)

[Deczkowska, A. et al, TREM2 as a therapeutic target (2017)](https://doi.org/10.1126/science.aan3888)